LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
- PMID: 40601072
- DOI: 10.1007/s10142-025-01635-9
LncRNAs in hypoxic microenvironment; insight in their impact in cancer biology
Abstract
Hypoxia may facilitate metastasis and tumor advancement in solid tumors. Intratumoral hypoxia may facilitate tumor aggressiveness by stabilizing hypoxia-inducible factor-1α (HIF-1α). Various transcriptional and epigenetic pathways modulate hypoxia-stimulated gene expression and tumor progression. Noncoding RNAs longer than 200 nt are long noncoding RNAs (lncRNAs). Current lncRNA profiling in several human tumor types revealed that lncRNA expression and deregulation vary by tumor type and may undergo transcriptional, genomic, and epigenetic modifications. LncRNAs controlled by hypoxia have emerged as a prominent focus in hypoxia-regulated biology due to their ability to influence multiple biological procedures associated with tumorigenesis. Hypoxia-regulated lncRNAs may influence tumor development, growth, anti-apoptosis, migration, invasion, angiogenesis, and tumor metabolism. In this light, hypoxia-inducible lncRNAs could interact with protein/protein complex and chromatin/epigenetic factors and another mechanism, thus favoring tumorigenesis. Conversely, lncRNAs may control hypoxia signaling by stabilizing HIF-1α via several mechanisms. Nonetheless, several undiscovered lncRNAs remain that may mediate or regulate the hypoxia axis. Consequently, the novel lncRNAs modulated by hypoxia or that influence hypoxia signaling have yet to be discovered and thoroughly described. Herein, we aim to classify suitable lncRNA targets to offer a feasible therapeutic modality for hypoxia-driven cancers.
Keywords: Cancer; Epigenetics; HIF-1α; Hypoxia; LncRNA.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Clinical trial number: Not applicable.
Similar articles
-
The role of LncRNA-MANCR induced by HIF-1α drive the malignant progression of pancreatic cancer by targeting miRNA-494/SIRT1 signaling axis under hypoxic conditions.Cancer Gene Ther. 2025 Jun;32(6):633-648. doi: 10.1038/s41417-025-00900-0. Epub 2025 Apr 7. Cancer Gene Ther. 2025. PMID: 40195439
-
A novel hypoxia-induced lncRNA, SZT2-AS1, boosts HCC progression by mediating HIF heterodimerization and histone trimethylation under a hypoxic microenvironment.Cell Death Differ. 2025 Apr;32(4):714-729. doi: 10.1038/s41418-024-01419-x. Epub 2024 Nov 22. Cell Death Differ. 2025. PMID: 39572656
-
Crosstalk between hypoxia-inducible factor (HIF) and lncRNAs in digestive tumors: from molecular mechanisms to clinical translation.Front Cell Dev Biol. 2025 Aug 8;13:1611889. doi: 10.3389/fcell.2025.1611889. eCollection 2025. Front Cell Dev Biol. 2025. PMID: 40861273 Free PMC article. Review.
-
New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.J Cancer Res Clin Oncol. 2021 Jul;147(7):1881-1895. doi: 10.1007/s00432-021-03584-9. Epub 2021 Mar 11. J Cancer Res Clin Oncol. 2021. PMID: 33693962 Free PMC article.
-
Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications.Oncol Res. 2024 Jul 17;32(8):1239-1256. doi: 10.32604/or.2024.052130. eCollection 2024. Oncol Res. 2024. PMID: 39055895 Free PMC article.
References
-
- Abulihaiti Z, Li W, Yang L, Zhang H, Du A, Tang N et al (2024) Hypoxia-driven lncRNA CTD-2510F5.4: a potential player in hepatocellular carcinoma’s prognostic stratification, cellular behavior, tumor microenvironment, and therapeutic response. Mol Biol Rep 51(1):905 - PubMed
-
- Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD et al (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61(3):439–448 - PubMed
-
- Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N et al (2021) Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth factor receptor–tyrosine kinase inhibitor: West Japan Oncology Group 8715L Phase 2 randomized clinical trial. JAMA Oncol 7(3):386–394 - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials